Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Caplacizumab speeds platelet normalization

Scully M et al. N Engl J Med. 2019 Jan 9. doi: 10.1056/NEJMoa1806311

Publish date:: January 23, 2019

Key clinical point: Patients with acquired thrombotic thrombocytopenic purpura (TTP) who were treated with caplacizumab has a significantly lower incidence of TTP-related deaths or recurrence.

Major finding: Time to platelet normalization was 2.69 days after treatment with caplacizumab, compared with 2.88 days with placebo (P=.01).

Study details: The double-blind, controlled HERCULES trial of 145 patients with TTP.

Disclosures: The study was funded by Ablynx. The study authors reported financial relationships with Ablynx and other companies.

Read the article here.

Citation:

Scully M et al. N Engl J Med. 2019 Jan 9. doi: 10.1056/NEJMoa1806311.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Bleeding Disorders

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

Hemochromatosis variants may confer 10-fold higher risk of liver cancer,

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,